Abstract
It is well established that ryanodine receptors (RyanRs) are overactive in Alzheimer’s disease (AD), and it has been suggested that inhibition of RyanR is potentially beneficial for AD treatment. In the present study, we explored a potential connection between basal RyanR activity and autophagy in neurons. Autophagy plays an important role in clearing damaged organelles and long-lived protein aggregates, and autophagy dysregulation occurs in both AD patients and AD animal models. Autophagy is known to be regulated by intracellular calcium (Ca2+) signals, and our results indicated that basal RyanR2 activity in hippocampal neurons inhibited autophagy through activation of calcineurin and the resulting inhibition of the AMPK (AMP-activated protein kinase)–ULK1 (unc-51-like autophagy-activating kinase 1) pathway. Thus, we hypothesized that increased basal RyanR2 activity in AD may lead to the inhibition of neuronal autophagy and accumulation of β-amyloid. To test this hypothesis, we took advantage of the RyanR2-E4872Q knock-in mouse model (EQ) in which basal RyanR2 activity is reduced because of shortened channel open time. We discovered that crossing EQ mice with the APPKI and APPPS1 mouse models of AD (both males and females) rescued amyloid accumulation and LTP impairment in these mice. Our results revealed that reduced basal activity of RyanR2-EQ channels disinhibited the autophagic pathway and led to increased amyloid clearance in these models. These data indicated a potential pathogenic outcome of RyanR2 overactivation in AD and also provided additional targets for therapeutic intervention in AD. Basal activity of ryanodine receptors controls neuronal autophagy and contributes to development of the AD phenotype.
SIGNIFICANCE STATEMENT It is well established that neuronal autophagy is impaired in Alzheimer’s disease (AD). Our results suggest that supranormal calcium (Ca2+) release from endoplasmic reticulum contributes to the inhibition of autophagy in AD and that reduction in basal activity of type 2 ryanodine receptors disinhibits the neuronal autophagic pathway and leads to increased amyloid clearance in AD models. Our findings directly link neuronal Ca2+ dysregulation with autophagy dysfunction in AD and point to additional targets for therapeutic intervention.
Introduction
Alzheimer's disease (AD) is an age-related brain disorder that causes progressive neurodegeneration predominantly in the cortical and hippocampal brain regions. Major hallmarks of AD are the progressive impairment of memory storage and the accumulation of fibrillary amyloid plaques in patient’s brains. Despite decades of research and effort, there is still no effective disease-modifying treatment for AD. Although amyloid pathology is a hallmark and defining feature of AD, targeting the amyloid pathway has been very challenging because of low efficacy and serious side effects. Alternative approaches or mechanisms for memory loss in AD need to be considered as potential therapeutic targets. Increasing studies suggest that neuronal calcium (Ca2+) dysregulation plays an important role in AD pathology (Bezprozvanny and Mattson, 2008; Popugaeva et al., 2015; Briggs et al., 2017). The expression and function of ryanodine receptor 2 (RyanR2), an intracellular Ca2+ release channel abundantly expressed in the hippocampus (HPC) and cortex (Furuichi et al., 1994; Giannini et al., 1995), are increased in animal models of familial AD (FAD) and in patients with early-stage sporadic AD (Kelliher et al., 1999; Smith et al., 2005; Chakroborty et al., 2009; Zhang et al., 2010; Bruno et al., 2012; Oulès et al., 2012; Liu et al., 2014; Lacampagne et al., 2017). Pharmacological inhibitors of RyanR such as dantrolene demonstrated beneficial effects in a variety of AD cellular and animal models (Chakroborty et al., 2012; Oulès et al., 2012; Peng et al., 2012; Lacampagne et al., 2017). In our previous studies, we used a genetic strategy and evaluated the effects of RyanR3 knockout (Liu et al., 2014) and a gating mutation in RyanR2 (Yao et al., 2020; Liu et al., 2021; Sun et al., 2021) in the context of AD mouse models. Some investigators suggested a mechanism that involves the rescue of neuronal hyperexcitability in AD mice (Liu et al., 2014; Yao et al., 2020; Liu et al., 2021; Sun et al., 2021), some suggest that blocking RyanR-mediated Ca2+ leakage may lead to decreased endoplasmic reticulum (ER) stress (Nakamura et al., 2021), some focused on the role of RyanR-mediated Ca2+ changes in synaptic function (Chakroborty et al., 2012); some suggested dantrolene can decrease β-secretase and γ-secretase activities and APP phosphorylation by affecting Cdk5 and GSk3β kinase activities (Oulès et al., 2012).
In this article, we would like to propose an alternative model that is based on direct connection between ER Ca2+ signaling and neuronal autophagy. Autophagy plays an important role in clearing damaged organelles and long-lived protein aggregates, and a substantial amount of evidence indicates that autophagy dysregulation occurs in both AD patients and animal models (Cataldo et al., 2004; Nixon et al., 2005; Yu et al., 2005; Boland et al., 2008; Yang et al., 2011; Sanchez-Varo et al., 2012; Liu and Li, 2019; Kuang et al., 2020; Chen et al., 2021; Zhang et al., 2021; Mustaly-Kalimi and Stutzmann, 2022). Autophagy is regulated by intracellular Ca2+ signals arising from different organelles, including ER and lysosomes. The role of inositol 1,4,5-trisphosphate receptors (InsP3Rs) in the regulation of autophagy had been intensively studied in nonexcitable cells, and InsP3R-mediated Ca2+ signals have been suggested to be involved in both inhibitory and stimulatory effects on autophagy (Lam et al., 2008; Cárdenas et al., 2010; Khan and Joseph, 2010; Decuypere et al., 2011a; 2011b; Valladares et al., 2018; Sukumaran et al., 2021). However, the role of RyanR in regulating autophagy is much less studied (Vervliet et al., 2017; Vervliet, 2018). Previous studies were mainly performed by overexpressing RyanRs in nonexcitable cells (Vervliet et al., 2017), or by using pharmacological modulators of RyanR activity that may exert off-target effects (Chung et al., 2016; Qiao et al., 2017; Law et al., 2019). As discussed in a recent review (Vervliet, 2018), a major issue in studying the role of RyanR in autophagy has been the lack of easy-to-use cellular models that express endogenous RyanR. As autophagy is easily influenced by many factors, expressing high levels of exogenous RyanR in cells that do not have adequate RyanR regulators may alter autophagy and other processes and introduce a variety of artifacts.
To resolve these problems in the present study we took advantage of RyanR2-E4872Q knock-in (KI) mouse model (EQ) in which RyanR2 activity is reduced because of shortened channel open time (Chen et al., 2014). Use of this model enabled us to evaluate the consequences of the reduction of endogenous RyanR2 activity in neuronal cells on autophagy and on AD-related phenotypes. The hypothesis that upregulated RyanR expression and activity in AD may be linked to autophagy dysregulation has been proposed previously (Vervliet et al., 2017; McDaid et al., 2020), but it has never been directly tested. Our results suggested that basal activity of RyanR2 inhibits autophagy via activation of calcineurin (CaN), which in turn inhibits the AMP-activated protein kinase (AMPK)– unc-51-like autophagy-activating kinase 1 (ULK1) pathway. Our results further suggested that reduced basal activity of RyanR2 in EQ mice reduced steady-state CaN activity, disinhibited autophagic pathway, and led to amyloid clearance and rescue of AD phenotype in APPKI and APPPS1 mouse models of AD. These data provided a novel pathogenesis signaling pathway for RyanR overactivation in a variety of AD models and may also provide additional targets for therapeutic manipulation in AD.
Materials and Methods
Mice.
The generation and characterization of RyanR2-E4872Q (EQ) mice was previously described (Chen et al., 2014). APPKI mice were provided by Takaomi Saido (RIKEN, Wako, Japan; Saito et al., 2014) and used in our previous studies (Zhang et al., 2016). APPPS1 mice (APPK670N; M671L; PS1L166P; Radde et al., 2006) were provided by Mathias Jucker (Tübingen University, Tübingen, Germany) and were also used in our previous studies (Zhang et al., 2010) . The colonies of all lines (on C57BL/6 background) were established at the University of Texas Southwestern Medical Center (UTSW) specific pathogen free barrier facility. Wild-type (WT) C57BL/6 were used in experiments as control mice. All procedures involving mice were approved by the Institutional Animal Care and Use Committee of UTSW, in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Both male and female mice were used in this study, and both sexes were balanced between groups, all the data presented are combined results from both sexes.
Materials.
FUW mCherry-GFP-LC3 (plasmid catalog #110060; Leeman et al., 2018) was obtained from Addgene. The lentivirus was generated by cotransfection of shuttle vectors with human immunodeficiency virus-1 packaging vector 8.9 and vesicular stomatitis virus glycoprotein G envelope glycoprotein plasmids into the packaging cell line HEK293T, as we described previously (Zhang et al., 2010).
Western blotting.
All protein samples were boiled at 95°C for 5 min, proteins were separated by SDS-PAGE and analyzed by Western blotting with the following antibodies: anti-LC3 (1:1000; catalog #NB100-2220, Novus Biologicals); anti-GAPDH (1:1000; catalog #MAB374, Millipore); anti-APP (1:2000; catalog #A8717, Sigma-Aldrich); anti-phospho-ULK1 (Ser555; D1H4) rabbit mAb (1:1000; catalog #5869, Cell Signaling Technology); anti-ULK1 (D8H5) rabbit mAb (1:1000; catalog #8054, Cell Signaling Technology); anti-phospho-AMPKα (Thr172; 40H9) rabbit mAb (1:1000; catalog #2535, Cell Signaling Technology); anti-AMPKα (D5A2) rabbit mAb (1;1000; catalog #5831, Cell Signaling Technology); anti-tubulin [1:1000; catalog #E7-c, Developmental Studies Hybridoma Bank (DSHB)]; anti-Akt antibody (1:1000; catalog #9272, Cell Signaling Technology); and anti-phospho-Akt (Ser473; 587F11) mouse mAb (1:1000; catalog #4051, Cell Signaling Technology). The HRP-conjugated anti-rabbit (1:3000; catalog #111-035-144) and anti-mouse (1:3000; catalog #115-035-146) secondary antibodies were from Jackson ImmunoResearch. For Western blot analysis, data were densitometrically analyzed using ImageJ software.
Primary hippocampal cultures.
The hippocampal cultures were established from postnatal day 0–1 pups and maintained in culture as we described previously (Zhang et al., 2010). Lenti-mCherry-GFP-LC3 infected neurons at 7 d in vitro (DIV7); at DIV15–16 cultures were treated with bafilomycin (BAF), ryanodine, FK506, or compound C for 4 h, then were lysed with 1× SDS-PAGE loading buffer for Western blot or fixing of the cells for confocal imaging.
Fura-2 calcium imaging.
DIV15−16 hippocampal cultures were maintained in artificial CSF (aCSF) as follows (in mm): 140 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, and 10 HEPES, at pH 7.3. The cells were loaded with fura-2 AM dye, and 340:380 nm ratio images were collected using a DeltaRAM-X illuminator, an IC-300 camera, and IMAGEMASTER PRO software (all from Photon Technology International). The region of interest used in the image analysis corresponded to the entire cell soma.
β-amyloid 40 and β-amyloid 42 measurements in hippocampal neuronal culture medium.
The hippocampal culture medium was collected at DIV15, and β-amyloid 40 (Aβ40) and Aβ42 concentrations were measured by ELISA (kit #KHB3481 and kit #KHB3441, Thermo Fisher Scientific) by following the instructions of the manufacturer. Since the corresponding cultures extract protein and use GAPDH Western blot as a loading control, Aβ40 and Aβ42 concentrations were normalized to their corresponding loading control for comparison between different culture wells.
Aβ40 and Aβ42 measurements from brain cortex homogenization.
Brain homogenization followed the instructions in the Thermo Fisher Scientific ELISA kits #KHB3481 and #KHB3441, which used 5 m guanidine HCl and 50 mm Tris HCl, at pH 8.0; the protein concentration was measured; the extract solutions were series diluted; Aβ40 and Aβ42 concentrations were measured using Thermo Fisher Scientific ELISA kits #KHB3481 and #KHB3441); and the data presented as Aβ40 and Aβ42 concentrations were normalized to their corresponding protein concentrations.
Immunohistochemistry.
Mice were terminally anesthetized and perfused transcardially with cold PBS followed by fixative (4% paraformaldehyde in PBS, pH 7.4). All brains were removed from skull and weighed. The brains were postfixed overnight at 4°C in 4% paraformaldehyde and equilibrated in 20–30% (w/v) sucrose in PBS. The brains were sliced into 50-μm-thick horizonal sections using a sliding microtome (model SM2000R, Leica). The brain sections were spaced 400 μm apart throughout from the position around interaural 4.96 to interaural 3.76, stained with rabbit anti-LC3 (1:250; catalog #12741, Cell Signaling Technology), rat anti-LAMP1 (1:250; catalog #1D4B, DSHB), and mouse anti-map2 (1:1000; catalog #mAB378, Chemicon), and followed by Alexa Fluor-488 secondary anti-rabbit IgG, Alexa Fluor-561 secondary anti-rat IgG, and Alexa Fluor-633 secondary anti-mouse IgG. Images visualized using a fluorescent confocal microscope (Leica) with a 63× oil-immersion objective. Acquisition parameters (such as laser power and gain) were kept constant for different samples. Image analysis was performed by using the ImageJ analysis software (Molecular Devices), threshold was kept constant for different samples. LC3 and LAMP1 puncta density were only analyzed in hippocampal CA1 neuron cell body layer region. Colocalization of LC3 with LAMP1 analysis was performed using the Coloc2 plugin.
Amyloid plaque staining.
The 50 μm horizontal brain sections spaced 400 μm apart throughout from the position around interaural 4.96 to interaural 3.76 were stained with 6E10 anti-Aβ mAb (1:1000; catalog #SIG-39300, Covance), followed Alexa Fluor-488 secondary anti-mouse IgG (1:2000). The quantitative analysis of amyloid load was performed blindly using the IsoCyte laser scanning system (Molecular Devices). The average intensity of the fluorescent signal of the plaques and the number of plaques in cortical and hippocampal areas were calculated automatically for each slice by using ImageJ analysis software (Molecular Devices).
Brain slice field recording.
Brain slices were prepared from 6-month-old animals of either sex. Mice were anesthetized and transcardially perfused with dissection buffer before decapitation. The brain was removed, dissected, and sliced in ice-cold dissection buffer containing the following (in mm): 2.6 KCl, 1.25 NaH2PO4, 26 NaHCO3, 0.5 CaCl2, 5 MgCl2, 212 sucrose, and 10 dextrose, using a vibratome (model VT 1000S, Leica). The 400 µm horizontal slices, which included HPC and lateral entorhinal cortex (LEC), were collected and transferred into a reservoir chamber filled with aCSF containing the following (in mm): 124 NaCl, 5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 2 CaCl2, 1 MgCl2, and 10 dextrose. Slices were allowed to recover for 2–5 h at 30°C. aCSF and dissection buffer were equilibrated with 95% O2/5% CO2. For recording, slices were transferred to a submerged recording chamber, maintained at 30°C, and perfused continuously with aCSF at a rate of 2–3 ml/min. Field potentials were recorded with extracellular recording electrodes (1 MΩ) filled with aCSF. The stimulation and recording pipettes were positioned in the outer molecular layer along the lateral perforant pathway (LPP). The function of LPP was validated by measurements of paired-pulse facilitation using 50 ms intervals between pulses as described previously (Colino and Malenka, 1993). Stimulus current was adjusted so that fEPSP stabilized at 40–50% of maximum. Baseline was recorded for at least 20 min until the differences among fEPSP slopes were within 10%. LEC–DG long-term potentiation (LTP) was induced by two bursts of high frequency stimulation (HFS) at 100 Hz for 1 s with 1 min intervals between pulses. Synaptic responses were recorded for at least 60 min after tetanization and quantified as the slope of the evoked fEPSP normalized to the baseline.
Statistical analysis.
Statistical comparisons of results obtained in experiments were performed by unpaired t test or one-way ANOVA with a Tukey’s HSD post hoc test. The p values are indicated in the text and figure legends, as appropriate. The differences between control and experimental groups were determined to be nonsignificant in cases in which p > 0.05.
Data availability.
All data are available in the main text.
Results
RyanR2-E4872Q (EQ) mutation increases autophagic flux in primary hippocampal neuronal cultures
To quantify autophagy in primary hippocampal neuronal cultures, we performed Western blotting experiments with antibodies against autophagic marker LC3II (Klionsky et al., 2021). The experiments were performed with lysates prepared from neurons maintained in normal culture media or treated with 400 nm lysosomal acidification inhibitor bafilomycin A1 (BAF) for 4 h. Robust autophagic flux in neurons has been previously reported on the basis of high LC3I/II ratio and accumulation of LC3II with BAF treatment (Rubinsztein et al., 2009; Klionsky et al., 2021). Once LC3-II is formed in neuronal cultures, it is quickly degraded by autophagic flux, and, in contrast with most other cell types, comparison of basal levels of LC3-I and LC3-II is not appropriate because of very low steady-state levels of LC3-II. Thus, in our studies we normalized LC3II (BAF) signal to GADPH loading control to reveal how much LC3-II is actually induced, and to quantify autophagic flux we calculated a ratio of LC3II(BAF)-LC3II(CON)/LC3II(BAF) for each culture treatment (Rubinsztein et al., 2009; Klionsky et al., 2021). In our experiments, we did not observe a significant change in LC3II(BAF)/GAPDH levels, although there is a trend that in APPKI neurons this ratio is slightly higher than in WT, and in EQ neurons this ratio is also slightly higher than in the corresponding control groups (Fig. 1A,B). However, we observed a significant increase in autophagic flux in EQ neurons when compared with wild-type neurons (Fig. 1A,B). When similar analysis was performed with primary neuronal cultures from APPKI mice and APPKI;EQ mice, we discovered that autophagic flux is somewhat reduced in APPKI neurons (this change did not reach a level of statistical significance), but autophagic flux is significantly enhanced in APPKI;EQ neurons (Fig. 1A,B).
To further evaluate autophagy in these neuronal cultures, we infected hippocampal neurons with lentiviruses encoding the mCherry-GFP-LC3 reporter construct (Leeman et al., 2018). The GFP signal is sensitive to the acidic and/or proteolytic conditions of the lysosome lumen, whereas mCherry is more stable. As a result, colocalization of GFP and mCherry fluorescence (visible as yellow) indicates a compartment that has not yet fused with a lysosome, such as autophagosome (AP; Leeman et al., 2018). In contrast, mCherry signal without GFP (free red) corresponds to an acidic autolysosome (AL; Leeman et al., 2018). If the cell autophagy flux is high, the GFP signal would be quenched in the lysosome, resulting in the low Yellow/Red ratio (Y/R%). In contrast, if the autophagy flux is low, then we expect to see more yellow puncta. Thus, the Y/R% observed with this indicator is inversely proportional to the autophagic flux in a cell. The results of our experiments confirmed that hippocampal neurons have constitutively robust autophagic flux (most puncta are free red puncta, with very low Y/R ratio; Fig. 1C,D). Comparison of Y/R ratios among WT, EQ, APPKI, and APPKI:EQ neurons suggested that there is a trend that EQ have higher flux than WT, and APPKI flux is slightly more impaired than WT, but these changes did not reach the level of significance (Fig. 1D). However. we found autophagic flux in APPKI;EQ neurons was significantly increased when compared with APPKI neurons (Fig. 1D). These conclusions are in agreement with the results of LC3II Western blotting analysis (Fig. 1A,B).
Basal RyanR2 activity regulates autophagy by modulating CaN-pAMPK–pULK1 pathway
The E4872Q (EQ) mutation in RyanR2 shortens channel open times (Chen et al., 2014), and we predicted that it should lead to a reduction of basal Ca2+ flux from the ER and reduced levels of neuronal cytosolic Ca2+ in the steady state. To test this hypothesis, we performed fura-2 imaging experiments and quantified basal cytosolic Ca2+ levels in wild-type, EQ, APPKI, and APPKI;EQ hippocampal neuronal cultures. We discovered that APPKI neurons have significantly higher basal Ca2+ levels than wild-type neurons, and EQ mutation significantly decreased basal Ca2+ levels in both EQ and APPKI;EQ neurons (Fig. 2A). Thus, we reasoned that enhanced autophagic flux in EQ and APPKI;EQ neurons (Fig. 1) may be because of reduced basal ER Ca2+ flux from the ER and reduced basal cytosolic Ca2+ levels. To test this hypothesis, we inhibited RyanR activity by treating wild-type, EQ, APPKI, and APPKI;EQ neurons with 50 μm ryanodine for 4 h in the presence and absence of BAF. The autophagy and autophagic flux were quantified by Western blotting of neuronal lysates for LC3II, as described above. Obtained results indicated that pharmacological inhibition of RyanR significantly increased autophagic flux in wild-type and APPKI neurons, but not in EQ and APPKI;EQ neurons (Fig. 2B,C), supporting our hypothesis regarding a role of RyanR in the control of neuronal autophagy. It has been reported that increased cytosolic Ca2+ is able to activate CaN, which in turn can suppress the AMPK-dependent autophagy pathway in cardiomyocytes (He et al., 2014). To test the importance of CaN in the regulation of neuronal autophagy, we exposed neuronal cultures to specific CaN inhibitor FK506 (1 μm for 4 h) and evaluated autophagy and autophagic flux by LC3II Western blotting of neuronal lysates. In these experiments, we discovered that FK506 was able to stimulate autophagic flux in wild-type and APPKI neurons, but not in EQ and APPKI;EQ neurons (Fig. 2B,C). Thus, the effects of FK506 were similar to the effects of ryanodine, and both effects were occluded by EQ mutation. To further confirm these findings, we infected neuronal cultures with lentiviruses encoding mCherry-GFP-LC3 reporter construct (Leeman et al., 2018) and performed quantification of autophagic flux by calculating Yellow/Red signal ratio, as described above. In these experiments, we discovered that pharmacological inhibition of RyanR by ryanodine significantly enhanced autophagic flux in APPKI neurons and that the inhibition of CaN by FK506 dramatically enhanced autophagic flux in all groups of neurons (Fig. 2D), suggesting a critical role of CaN in the control of neuronal autophagy.
Activation of CaN has been shown to control autophagy by suppressing activity of AMPK in cardiomyocytes (He et al., 2014). To determine whether a similar signaling pathway operates in neurons, we performed Western blotting experiments with antibodies specific for total AMPK and for the phosphorylated form pAMPK. These experiments were performed with lysates prepared from wild-type, EQ, APPKI, and APPKI;EQ neuronal cultures. In addition to the AMPK pathway, we also evaluated the AKT pathway, which is also known to modulate autophagy through a mammalian target of rapamycin (mTOR)-dependent signaling network (Al-Bari and Xu, 2020). We discovered that the pAKT/AKT ratio was decreased in APPKI neurons, but the EQ mutation did not induce significant changes in pAKT/AKT ratio (Fig. 3A,B), suggesting that this pathway is not responsible for the increase in autophagic flux observed in EQ neurons. In contrast, the pAMPK/AMPK ratio was significantly increased in EQ neurons (Fig. 3A,B), and its increase almost reached a level of statistical significance in APPKI;EQ neurons (Figs. 3A,B). These results supported the hypothesis that basal Ca2+ release from ER via RyanR2 modulates levels of neuronal autophagy via CaN–AMPK pathway, which is similar to conclusions reached in studies of autophagy in cardiomyocytes (He et al., 2014). Consistent with this conclusion, we demonstrated that AMPK inhibitor dorsomorphin (compound C; Lu et al., 2014) almost completely blocked the autophagosome fusion with lysosome in neuronal cultures using the mCherry-GFP-LC3 assay (Fig. 3E).
In nonexcitable cells, AMPK controls autophagy by phosphorylating and activating ULK1 at position Ser555 (Egan et al., 2011). To determine whether the same pathway is involved in the control of neuronal autophagy, we performed Western blotting experiments with antibodies specific for pULK1-Ser555. We determined that EQ mutation significantly increased the pULK1-Ser555/ULK1 ratio in both wild-type and APPKI neurons (Fig. 3A,B). To confirm that the activation of AMPK and ULK1 kinases in EQ neurons is indeed because of reduced RyanR2 and CaN activity, we treated these neurons with ryanodine (50 μm ryanodine for 4 h) or with FK506 (1 μm for 4 h). In these experiments, we observed that ryanodine treatment resulted in increased pAMPK/AMPK and pULK1-Ser555/ULK1 ratios in both wild-type and APPKI neurons (Fig. 3C,D). However, there was no difference in pAMPK/AMPK or pULK1-Ser555/ULK1 ratios between wild-type and EQ or APPKI and APPKI:EQ in the presence of ryanodine (Fig. 3C,D). On both readouts, the effects of FK506 treatment were similar to the effects of ryanodine (Fig. 3C,D). Based on results obtained in this series of biochemical experiments (Figs. 2, 3), we proposed that basal activity of RyanR2 regulates neuronal autophagic flux by activating CaN, which in turn inhibits the pAMPK–pULK1-Ser555 pathway, and that the EQ mutation in RyanR2 can disinhibit this pathway and promote neuronal autophagic flux (Fig. 1).
In addition to regulating the phosphorylation of AMPK, CaN may also enhance the transcription of genes that are involved in autophagy and lysosomal function, such as LC3 and several others (Sardiello et al., 2009; Settembre et al., 2012; Medina et al., 2015) through dephosphorylation of transcription factor EB (TFEB). However, in our experiments EQ mutation did not have a significant effect on the total levels of LC3 (Figs. 1-3) or pTFEB (data not shown), indicating that transcriptional changes are not likely to be responsible for the observed stimulation of autophagy in cultured hippocampal neurons. We also detected the total levels of Beclin 1, a protein involved in the early events of AP formation. We found that neither EQ mutation nor ryanodine or FK506 treatment induced significant changes in Beclin 1 levels (data not shown), consistent with the published data (Vervliet et al., 2017; Vervliet, 2018). However, we cannot fully exclude that RyanR2 activity may also affect earlier steps in the autophagy process via influencing other targets beyond the scope of current study.
RyanR2-E4872Q (EQ) mutation upregulate autophagy pathway in vivo
Results obtained in experiments with primary hippocampal neuronal cultures (Figs. 1-3) enabled us to propose the hypothesis that reduced basal Ca2+ release from ER because of E4872Q (EQ) gating mutation in RyanR2 leads to the stimulation of neuronal autophagy. To study the autophagy–lysosomal pathway changes in vivo, we performed a series of immunostaining experiments with hippocampal slices from 6-month-old mice using antibodies against LC3 and lysosomal marker LAMP1 (Fig. 4A). MAP2 staining was used to identify neuronal cells in these experiments (Fig. 4A). To quantify these results, we analyzed total LC3 and LAMP1-positive puncta in hippocampal CA1 neurons and calculated a fraction of LC3 colocalized with LAMP1 and the fraction of LAMP1 colocalized with LC3. Similar to experiments with neuronal cultures, we performed experiments with slices from wild-type and EQ mice, as well as from APPKI and APPKI;EQ mice. In addition, we also analyzed APPPS1 and APPPS1;EQ mice. We included APPPS1 mice as it is a more aggressive model of amyloidosis than that in APPKI mice (Radde et al., 2006). APPS1 mice start to accumulate amyloid plaques at a very young age (6–8 weeks), while it takes up to 12 months for amyloid plaques to become visible in brain samples from APPKI mice. Therefore, analysis of these two AD mouse models enabled us to compare signaling pathways acting upstream or downstream of Aβ amyloidosis (Saito et al., 2014). Consistent with results obtained in neuronal cultures, we discovered that EQ mutation resulted in a significant increase in LC3 staining when compared with the wild-type mice (Fig. 4A,B), suggesting stimulation of neuronal autophagy in these mice. We also discovered that APPPS1 mice have increased LC3 staining when compared with wild-type and APPKI mice (Fig. 4A,B), consistent with reports that indicated upregulated autophagosome formation as a result of amyloid plaque accumulation (Long et al., 2020). Interestingly, EQ mutation also significantly increased LC3 staining in both APPKI and APPPS1 mouse lines (Fig. 4B), suggesting drastic upregulation of autophagy. We also discovered that both APPKI and APPPS1 mice show reduced LAMP1 staining when compared with wild-type mice (Figs. 4A,C), consistent with the reduced expression of lysosomal markers in the brains of AD patients and mouse models (Long et al., 2020). Remarkably, EQ mutation rescued the LAMP1 staining signal to the wild-type levels in both AD models (Fig. 4A,C). We also calculated LC3 colocalization with LAMP1 and LAMP1 colocalization with LC3 using the Manders coefficient of colocalization (MCC) and discovered that MCC values were significantly decreased in both APPKI and APPPS1 hippocampal CA1 neurons, which indicate impaired AL formation (Fig. 4D,E) . In contrast, EQ mutation significantly rescued this defect in APPS1 mice (Fig. 4D,E) and showed a rescue trend in APPKI mice (p = 0.054; Fig. 4D). All of these in vivo results suggest that EQ mutations greatly upregulate the autophagy–lysosomal pathway in neurons and that AD neurons display autophagy–lysosomal fusion dysfunction at a very early stage, which can be fully rescued in vivo by EQ mutation in RyanR2. This defect and autolysosome acidification defects in AD neurons that have been reported previously (Lee et al., 2010, 2015, 2022; Mustaly-Kalimi and Stutzmann, 2022) may work together in the AD pathogenesis pathway.
RyanR2-E4872Q (EQ) mutation promotes APP and C99 degradation in APPKI neurons
In agreement with the known role of autophagy in the processing of APP (Liu and Li, 2019; Rahman et al., 2021), we discovered that treatment with BAF significantly increased the levels of full-length APP in APPKI neurons (Fig. 5A,B). Consistent with increased autophagic flux in APPKI;EQ neurons, the levels of full-length APP were significantly decreased in APPKI;EQ neurons (Fig. 5A,B). APP-C-terminal fragment (CTF; C99) and intracellular C-terminal domain (AICD) fragments of APP proteolysis have been reported to be degraded by the autolysomal pathway (Vingtdeux et al., 2007). Indeed, we observed the accumulation of AICD following BAF treatment of APPKI and APPKI;EQ neurons (Fig. 5A). The levels of the APP-CTF (C99) fragment were reduced in APPKI;EQ neurons (Fig. 5A,C). However, in bafilomycin-treated neurons, the APP-CTF (C99) fragment levels were greatly decreased (Fig. 5A,C), most likely because of the inhibition of BACE1-mediated APP processing caused by bafilomycin treatment (Haass et al., 1995; Evrard et al., 2018). We can barely detect C83 fragment from α-cleavage in APPKI neurons because the Swedish mutations in APP facilitate β-cleavage. Consistent with a reduction in APP and APP-CTF (C99) levels, we detected a reduction in Aβ40 and Aβ42 levels in the culture media of APPKI;EQ neurons when compared with APPKI neurons without significant changes in Aβ42/Aβ40 ratio (Fig. 5D).
RyanR2-E4872Q (EQ) mutation reduces amyloid plaque accumulation and rescues LTP defects in AD mice
Since we discovered that EQ mutation in RyanR2 promotes APP degradation by autophagy and decreases levels of Aβ40 and Aβ42 in experiments with APPKI neuronal cultures (Fig. 5), we evaluated the effects of EQ mutation on amyloid pathology in vivo. In our analysis, we observed a significant reduction in amyloid plaque numbers and intensity in the hippocampal region of 6-month-old APPS1;EQ mice when compared with age-matched APPPS1 mice (Fig. 6A,B). To understand the reasons for the reduction in plaque load, we prepared homogenates from cortical tissue of 6-month-old APPPS1 and APPPS1;EQ mice and measured the concentration of Aβ42 and Aβ40 by ELISA. We discovered that, in agreement with in vitro culture data (Fig. 5), both Aβ42 and Aβ40 levels were significantly decreased in APPPS1;EQ cortical homogenates (Fig. 6C). However, we found that the Aβ42/Aβ40 ratio is significantly increased in APPPS1;EQ cortical samples, which we did not observe in vitro (Fig. 5C). It is possible that changes in the ratio are because of changes in lysosomal function in the aging APPPS1;EQ mice, as it has been shown that cathepsin D changes can regulate this Aβ42/Aβ40 ratio (Suire et al., 2020) or some unknown γ-secretase changes in old APPPS1;EQ mice, which we can investigated in the future. Because of the less severe phenotype, we compared amyloid load in hippocampal region of 13-month-old APPKI and APPKI;EQ mice. In this analysis, we discovered a trend in the reduction of amyloid plaque numbers and intensity in APPKI;EQ mice that did not reach a level of statistical significance (Fig. 7A,B), most likely because of the small numbers of plaques observed in this model.
To access the effects of EQ mutation on synaptic function, we performed measurements of LTP using brain slices. The EC–hippocampal circuit is critically involved in memory formation (Buzsáki and Moser, 2013), and dysfunction of this circuit has been identified in the earliest stages of AD. The LEC develops tau tangles and amyloid plaques before other regions of the brain (Braak and Braak, 1991; Braak and Del Tredici, 2015). Consistent with previous reports (Radde et al., 2006; Zhang et al., 2016), we determined that LTP in the lateral perforant pathway was impaired at 6 months of age for both APPPS1 (Fig. 6C,D) and for APPKI (Fig. 7C,D) mice when compared with wild-type age-matched mice. Importantly, these LTP defects were rescued in both APPPS1;EQ (Fig. 6C,D) and APPKI;EQ (Fig. 7C,D) mice.
Discussion
AD is characterized by the accumulation of abnormal protein aggregates including amyloid plaques (composed of Aβ peptides) and neurofibrillary tangles (formed by hyperphosphorylated tau protein). Despite extensive research, the molecular basis underlying AD pathogenesis is still not fully understood, and there are no effective treatments to block or reverse AD progression. Autophagy plays an important role in clearing damaged organelles and long-lived protein aggregates and neuronal cells depend heavily on autophagy to clear large and insoluble protein aggregates to maintain protein homeostasis (Malampati et al., 2020). Accumulating evidence indicates that impaired autophagy contributes to AD pathogenesis (Liu and Li, 2019; Kuang et al., 2020; Chen et al., 2021; Zhang et al., 2021; Mustaly-Kalimi and Stutzmann, 2022). For example, it has been suggested that FAD mutations in presenilins may impair autophagy through defective lysosomal acidification or reduced lysosomal Ca2+ content (Lee et al., 2010, 2015; Coen et al., 2012; Fedeli et al., 2019; for review, see Bezprozvanny, 2012). There is also a growing body of evidence that dysregulation in neuronal Ca2+ signaling plays a major role in the initiation of AD pathogenesis (Bezprozvanny and Mattson, 2008; Popugaeva et al., 2015; Briggs et al., 2017). RyanR-mediated Ca2+ signaling is upregulated in early-stage AD patients and FAD mouse models (Kelliher et al., 1999; Stutzmann et al., 2006; Supnet et al., 2006; Zhang et al., 2010; Bruno et al., 2012). Previous reports demonstrated that genetic or pharmacological inhibition of RyanR activity in AD mouse models resulted in beneficial effects, such as improved synaptic plasticity and the normalization of behavioral and cognitive functions with or without reduced amyloid load (Chakroborty et al., 2012; Oulès et al., 2012; Peng et al., 2012). Possible connections between neuronal Ca2+ dysregulation and autophagy in AD has been proposed (Filadi and Pizzo, 2019). It has been suggested that the upregulation of RyanR expression and activity may lead to the dysregulation of autophagy (Vervliet et al., 2017; McDaid et al., 2020), but no experimental evidence was provided in support of this hypothesis.
In the present study, we took advantage of the RyanR2-E4872Q KI mouse model (EQ) in which RyanR2 activity is reduced because of shortened channel open time (Chen et al., 2014). Use of this model enabled us to evaluate the consequences of the reduction of endogenous RyanR2 activity in neuronal cells for autophagy and for AD-related phenotypes. Based on the obtained results, we propose a model that directly links basal activity of RyanR2 to neuronal autophagy (Fig. 8A). In this model, we propose that basal Ca2+ activity of RyanR2 in neuronal cells leads to continuous activation of CaN, which in turn inhibits the AMPK–ULK1 pathway that regulates the autophagic flux. In EQ neurons, the reduction of RyanR2 activity because of the EQ mutation leads to reduced activity of CaN and disinhibition of the AMPK–ULK1 pathway, resulting in enhanced autophagic flux (Fig. 8B). Similar effects are achieved as a result of RyanR inhibition by ryanodine (Figs. 2, 3). The proposed model is also supported by our results with specific CaN inhibitor FK506, that resulted in the activation of AMPK and ULK1 and a dramatic upregulation of neuronal autophagy (Figs. 2, 3). Our model of control of neuronal autophagy by RyanR2 and Ca2+ (Fig. 8A) is similar to the model that was proposed previously in cardiomyocytes (He et al., 2014). It should be noted that cytosolic Ca2+ signals may also trigger autophagy. For example, it has been reported that the activation of RyanR may induce autophagy-dependent cell death by stimulating the CaMKK2–AMPK–mTOR signaling pathway (Chung et al., 2016; Law et al., 2019). To reconcile these results with our conclusions, we propose that low levels of basal Ca2+ flux because of spontaneous activity of RyanR2 primarily stimulate CaN and inhibit autophagy, but high levels of Ca2+ during evoked Ca2+ release lead to the activation of CaMKK2, which promotes autophagy. Both CaN and CaMKK2 are regulated by Ca2+/calmodulin, and differential modulation of CaN and CaMKII by low and high Ca2+ elevations has already been described (Saucerman and Bers, 2008; Stefan et al., 2008).
We further propose that overactivation of RyanR2 and Ca2+ release from ER contributes to impaired autophagy in early AD (Fig. 8C). Specifically, we reasoned that overloaded ER Ca2+ stores and/or increased expression of RyanR2 leads to increased basal Ca2+ flux and overactivation of CaN. Overactivation of CaN leads to further suppression of the AMPK–ULK1 pathway and reduced autophagy. In turn, reduced autophagy impairs the clearance of APP and APP proteolytic fragments, eventually leading to the accumulation of soluble Aβ42 oligomers, amyloid plaques, and impaired synaptic plasticity. This model is supported by the observation of reduced autophagic flux and reduced pAMPK/AMPK levels in APPKI neurons (Figs. 1, 3). Based on this hypothesis, we can explain the beneficial effects of the RyanR2 EQ mutation in AD models (Fig. 8D). We propose that the reduction of Ca2+ flux from ER in AD;EQ neurons normalizes CaN activity and causes disinhibition of the AMPK–ULK1 pathway and stimulation of autophagy. This idea is supported by our observation of autophagic flux rescue in APPKI neurons in the presence of the EQ mutation or following pharmacological inhibition of RyanR with ryanodine or inhibition of CaN with FK506 (Figs. 1-4). It is also supported by the rescue of autophagy in the APPPS1;EQ mouse model (Fig. 4). We further propose that increased autophagy leads to enhanced clearance of APP and APP fragments, reduction in the levels of soluble Aβ42 oligomers and amyloid plaques, and rescue of LTP defects. This idea is supported by the observation of reduced APP and APP-CTF levels and reduced amounts of Aβ40 and Aβ42 in culture media of APPKI;EQ neurons (Fig. 5); reduced plaque load and reduced Aβ40 and Aβ42 concentrations in cortex homogenates in APPPS1;EQ mice (Fig. 6); and rescue of LTP defects in both APPKI;EQ and APPPS1;EQ mice (Figs. 6, 7). Interestingly, previous studies suggested beneficial effects of CaN inhibition in multiple models of AD (Dineley et al., 2007, 2010; Taglialatela et al., 2009; Wu et al., 2010; D’Amelio et al., 2011; Rozkalne et al., 2011; Kim et al., 2015; Stallings et al., 2018). Moreover, post hoc analysis of epidemiological data revealed that the incidence of AD was significantly reduced in transplant patients chronically treated with FK-506 (Taglialatela et al., 2015). It is possible that some of these beneficial effects observed with FK506 and other CaN inhibitors in AD are also related to stimulation of neuronal autophagy as our model suggests (Fig. 8).
Comparison of results obtained with APPKI and APPS1 mice enabled us to compare effects on autophagy before and after amyloidosis. At 6 months of age, the levels of LC3-positive autophagosomes were upregulated in APPPS1 mouse brains but not in APPKI mouse brains (Fig. 4). However, both APPPS1 and APPKI mouse brains displayed decreased LAMP1-positive lysosomal puncta and decreased autolysosome at the same age (Fig. 4). Since APPPS1 mice, but not APPPKI mice, display amyloid plaques at this age, our results suggest that impaired autophagy-lysosomal function is an early event (before plaque formation) in the AD pathogenesis pathway, and that ER Ca2+ overload and upregulation of RyanR2 activity in early AD may contribute to these problems. We propose that the upregulation of autophagosome formation is more likely to be a late-stage compensatory mechanism induced in response to amyloid plaque burden. Our results suggest that the upregulation of autophagosome formation in APPPS1 mice is not enough to rescue neurons from damage, but the EQ mutation disinhibits the autophagic flux defect and leads to a rescue effect in APPS1;EQ mice. This conclusion is consistent with previous and recent reports (Lauritzen et al., 2016; Long et al., 2020; Lee et al., 2022). It is also consistent with the idea that autophagy is constitutively active and highly efficient in healthy neurons (Fig. 1) and that the autophagic pathology observed in late AD most likely arises from impaired clearance of autophagic vacuoles (AVs) rather than from strong autophagy induction (Boland et al., 2008). Additionally, AMPK–ULK1 pathways were also important for mitophagy regulation (Fang et al., 2019); impaired mitophagy is also important for AD pathogenesis (Ye et al., 2015; Vaillant-Beuchot et al., 2021; Mary et al., 2023), so overactivation of the RyanR-mediated CaN–AMPK–ULK1 pathway may also be abnormal and involved in mitophagy in AD.
It should also be noted that previous studies also demonstrated the benefit of crossing EQ mice with 5XFAD or 3xTg-AD mouse models of AD (Yao et al., 2020; Liu et al., 2021; Sun et al., 2021). These authors observed improved synaptic plasticity and rescue of cognitive functions without significant changes in amyloid load. This is in contrast to our studies performed with APPPS1 and APPKI mice. It is possible that the amyloid load in 5xFAD mice is very large and upregulation of autophagic pathway may not be sufficient to significantly reduce it. It is also possible that reduced activity of RyanR2 exerts multiple beneficial effects in addition to the upregulation of autophagy. CaN has many other downstream targets, for example, the pCREB pathway, which is also important for synaptic plasticity and has been implicated in memory impairment in AD (Saura and Valero, 2011; Amidfar et al., 2020). In our studies, we found in APPKI;EQ hippocampal cultures pCREB/CREB was significantly increased compared with APPKI cultures (data not shown), suggesting that this pathway may also play some role in the rescue effects in APPKI;EQ mice. In addition to the CaN signaling pathway, it also has been suggested that the inhibition of RyanR2 may lead to the rescue of AD-associated neuronal hyperexcitability (Yao et al., 2020; Liu et al., 2021; Sun et al., 2021), reduction in ER stress (Nakamura et al., 2021), and direct effects on β-secretase and γ-secretase activities and APP phosphorylation (Oulès et al., 2012). The model proposed here (Fig. 8D) provides a novel potential explanation for the benefits of pharmacological inhibition of RyanR in AD and may also provide an additional target for therapeutic intervention in AD.
Footnotes
This research was funded by National Institutes of Health Grants R56-AG-071310 (to I.B.) and R01-AG-055577 (to I.B.), Russian Science Foundation Grant 20-45-01004 (to I.B.), and Canadian Institutes of Health Research Grant PJT-152914 (to S.R.W.C.). I.B. holds the Carl J. and Hortense M. Thomsen Chair in Alzheimer’s Disease Research. We thank Dr. Meewhi Kim and Dr. Volodya Zhemkov for comments on the manuscript and helpful discussions.
I.B. is a member of the scientific advisory board of Neurodon, LLC. S.R.W.C. filed a Patent Cooperation Treaty application for “Methods of Treating and/or Preventing Alzheimer’s Disease with R-carvedilol.” The authors declare no other competing financial interests.
- Correspondence should be addressed to Ilya Bezprozvanny at Ilya.Bezprozvanny{at}UTSouthwestern.edu